gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Naxitamab binds GD2 on tumor cells; its Fc engages CD16a on NK cells to trigger ADCC (and complement), killing GD2+ tumor cells. CD16a-expressing cells serve as effectors and are not directly targeted or killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated interaction enabling ADCC by NK cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06026657
disease_id_num_tar_ref
1413
drug_id_num_tar_ref
3820